ストックスクリーナーアプリを入手
7.57
2.07%
-0.16
アフターアワーズ：
7.52
-0.05
-0.66%
前日終値:
$7.73
開ける：
$7.8
24時間の取引高:
278.09K
Relative Volume:
1.00
時価総額：
$271.38M
収益：
-
当期純損益:
-
株価収益率:
-
EPS:
-
ネットキャッシュフロー:
-
1週間 パフォーマンス:
-0.39%
1か月 パフォーマンス:
+28.74%
6か月 パフォーマンス:
+80.24%
1年 パフォーマンス:
-67.92%
1日の値動き範囲:
$7.52
$7.87
1週間の範囲:
$7.245
$8.15
52週間の値動き範囲:
$2.88
$24.00
Bioage Labs Inc Stock (BIOA) Company Profile
BIOA を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
BIOA
Bioage Labs Inc
|
7.57 | 277.12M | 0 | 0 | 0 | 0.00 |
|
ZTS
Zoetis Inc
|
144.09 | 63.86B | 9.39B | 2.62B | 2.22B | 5.8121 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.44 | 41.80B | 29.96B | 957.25M | 4.77B | 0.2956 |
|
HLN
Haleon Plc Adr
|
9.27 | 40.88B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
20.48 | 22.98B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
445.43 | 19.53B | 3.08B | 1.24B | 1.07B | 25.61 |
Bioage Labs Inc Stock (BIOA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-10-22 | アップグレード | Citigroup | Neutral → Buy |
| 2025-02-28 | 開始されました | William Blair | Mkt Perform |
| 2024-12-10 | ダウングレード | Morgan Stanley | Overweight → Underweight |
| 2024-12-09 | ダウングレード | Citigroup | Buy → Neutral |
| 2024-12-09 | ダウングレード | Jefferies | Buy → Hold |
| 2024-10-21 | 開始されました | Citigroup | Buy |
| 2024-10-21 | 開始されました | Jefferies | Buy |
| 2024-10-21 | 開始されました | Morgan Stanley | Overweight |
すべてを表示
Bioage Labs Inc (BIOA) 最新ニュース
Is BioAge Labs Inc. stock attractive for long term wealth buildingMarket Risk Report & Pattern Based Trade Signal System - newser.com
Analyzing BioAge Labs Inc. with risk reward ratio chartsPortfolio Value Report & Consistent Income Trade Recommendations - newser.com
Using data models to predict BioAge Labs Inc. stock movementQuarterly Trade Report & Fast Moving Stock Watchlists - newser.com
How strong is BioAge Labs Inc. (Y7G) stock earnings growthJuly 2025 Volume & Trade Opportunity Analysis - newser.com
Sector ETF performance correlation with BioAge Labs Inc.2025 Trading Volume Trends & Precise Trade Entry Recommendations - newser.com
Obesity Drugmaker Escapes Clinical Trial Securities Suit - Law360
BioAge Labs (NASDAQ:BIOA) Given Sell (D-) Rating at Weiss Ratings - MarketBeat
BioAge Beats IPO Investor Lawsuit Over Weight Loss Trial End - Bloomberg Law News
Why BioAge Labs Inc. (Y7G) stock stays undervaluedMarket Volume Report & Free High Accuracy Swing Entry Alerts - newser.com
Is BioAge Labs Inc. (Y7G) stock supported by free cash flow2025 Big Picture & Technical Entry and Exit Alerts - newser.com
Does BioAge Labs Inc. show high probability of reboundJuly 2025 Decliners & Expert Approved Momentum Trade Ideas - newser.com
How BioAge Labs Inc. stock compares to growth peers2025 Major Catalysts & AI Powered Buy/Sell Recommendations - newser.com
Automated trading signals detected on BioAge Labs Inc.July 2025 Fed Impact & High Accuracy Investment Signals - newser.com
Analyzing drawdowns of BioAge Labs Inc. with statistical toolsJuly 2025 Decliners & Expert Approved Momentum Trade Ideas - newser.com
Can BioAge Labs Inc. stock resist sector downturnsQuarterly Profit Report & Comprehensive Market Scan Insights - newser.com
Order flow analysis tools used on BioAge Labs Inc.CEO Change & Weekly Market Pulse Updates - newser.com
Published on: 2025-10-30 23:35:20 - newser.com
BioAge Labs, Inc. (NASDAQ:BIOA) Short Interest Update - MarketBeat
Why BioAge Labs Inc. stock could be next big winnerBull Run & Verified Stock Trade Ideas - newser.com
What candlestick patterns are forming on BioAge Labs Inc.Market Weekly Review & AI Driven Price Predictions - newser.com
Citigroup Maintains BioAge Labs (BIOA) Buy Recommendation - Nasdaq
Bioage Labs (BIOA) Receives Raised Price Target from Citigroup | - GuruFocus
Could This Anti-Obesity Drug Biotech Be Poised to Soar in 2026? - AOL.com
BioAge Labs (BIOA) Price Target Increased by 71.43% to 8.16 - Nasdaq
Patterns Watch: Will BioAge Labs Inc. stock benefit from upcoming earnings reportsMarket Growth Review & Stock Timing and Entry Methods - Fundação Cultural do Pará
Positive Week for BioAge Labs, Inc. (NASDAQ:BIOA) Institutional Investors Who Lost 68% Over the Past Year - 富途牛牛
Will BioAge Labs Inc. stock benefit from infrastructure spendingJuly 2025 Snapshot & Weekly Setup with High ROI Potential - Fundação Cultural do Pará
Published on: 2025-10-27 22:26:35 - newser.com
BioAge Labs files to sell 2.23M shares of common stock for holders - MSN
Bioage Labs Inc (BIOA) 財務データ
Bioage Labs Inc (BIOA) の財務データはありません。詳細については、他の銘柄を確認してください。
収益
当期純利益
現金流量
EPS
3.18%
1.86%
大文字化:
|
ボリューム (24 時間):